Ligand Pharmaceuticals Incorporated
LGND
$104.97
$0.350.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.03M | 45.24M | 42.14M | 96.34M | 52.15M |
| Total Depreciation and Amortization | 35.24M | 35.53M | 35.96M | 36.17M | 36.52M |
| Total Amortization of Deferred Charges | 2.61M | 2.45M | 2.08M | 2.00M | 1.98M |
| Total Other Non-Cash Items | 43.87M | 1.65M | 3.76M | -66.09M | -6.67M |
| Change in Net Operating Assets | 19.36M | -8.24M | -36.19M | -34.06M | -34.40M |
| Cash from Operations | 97.05M | 76.64M | 47.76M | 34.36M | 49.58M |
| Capital Expenditure | -1.82M | -1.53M | -1.42M | -1.21M | -3.52M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | -10.41M | -10.41M | -10.41M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -141.84M | -113.80M | -76.50M | -14.39M | 2.24M |
| Cash from Investing | -143.66M | -115.33M | -88.32M | -26.01M | -11.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -25.00K | -24.00K | -28.00K | -76.89M | -76.90M |
| Issuance of Common Stock | 102.73M | 52.78M | 34.77M | 34.36M | 22.45M |
| Repurchase of Common Stock | -5.14M | -3.46M | -3.44M | -3.47M | -4.55M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -426.00K | 32.77M | -1.05M | -990.00K | -949.00K |
| Cash from Financing | 97.14M | 82.07M | 30.26M | -46.99M | -59.95M |
| Foreign Exchange rate Adjustments | -1.17M | 377.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.35M | 43.76M | -10.31M | -38.64M | -22.05M |